Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Bought by Vontobel Holding Ltd.

Vontobel Holding Ltd. grew its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 137.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,424 shares of the company’s stock after purchasing an additional 824 shares during the quarter. Vontobel Holding Ltd.’s holdings in Medpace were worth $475,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Mather Group LLC. acquired a new stake in Medpace in the first quarter valued at $28,000. Fidelis Capital Partners LLC purchased a new position in shares of Medpace in the 1st quarter valued at about $31,000. J.Safra Asset Management Corp raised its position in shares of Medpace by 87.0% during the 1st quarter. J.Safra Asset Management Corp now owns 101 shares of the company’s stock worth $41,000 after acquiring an additional 47 shares in the last quarter. DT Investment Partners LLC purchased a new stake in Medpace during the second quarter worth approximately $41,000. Finally, Ashton Thomas Private Wealth LLC acquired a new position in Medpace in the second quarter valued at approximately $52,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have weighed in on MEDP shares. Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and cut their price objective for the stock from $415.00 to $345.00 in a report on Wednesday, September 25th. Guggenheim reduced their price target on shares of Medpace from $464.00 to $432.00 and set a “buy” rating for the company in a research report on Wednesday, July 24th. StockNews.com lowered Medpace from a “buy” rating to a “hold” rating in a report on Friday, September 27th. William Blair reissued an “outperform” rating on shares of Medpace in a report on Wednesday, September 11th. Finally, Deutsche Bank Aktiengesellschaft decreased their target price on Medpace from $395.00 to $336.00 and set a “hold” rating for the company in a research report on Wednesday, July 24th. Five equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, Medpace currently has an average rating of “Moderate Buy” and a consensus target price of $394.00.

Medpace Trading Down 1.0 %

Medpace stock opened at $352.92 on Tuesday. The stock has a 50 day moving average of $355.97 and a two-hundred day moving average of $383.09. Medpace Holdings, Inc. has a twelve month low of $227.21 and a twelve month high of $459.77. The stock has a market capitalization of $10.93 billion, a price-to-earnings ratio of 35.98, a PEG ratio of 1.77 and a beta of 1.35.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, July 22nd. The company reported $2.75 earnings per share for the quarter, topping the consensus estimate of $2.54 by $0.21. Medpace had a return on equity of 55.14% and a net margin of 16.74%. The firm had revenue of $528.10 million during the quarter, compared to the consensus estimate of $528.41 million. The company’s revenue for the quarter was up 14.6% on a year-over-year basis. During the same period last year, the company earned $1.93 earnings per share. Equities analysts predict that Medpace Holdings, Inc. will post 11.64 earnings per share for the current year.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.